Clinical Trials
2 trialsNCT07015242 2026-03-24
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT02405676 2026-03-19
BNHL-2015
Children's Cancer Group, China
Phase 2/3 Active not recruiting